(18)F-PSMA-11

Also Known As:

18F-PSMA-11

Networked: 9 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Dicarboxylic Acids: 108
      - Glutarates: 35
        (18)F-PSMA-11: 9
- Organophosphorus Compounds: 300
  - Phosphinic Acids: 18
    - (18)F-PSMA-11: 9
Inorganic Chemicals: 9
- Acids: 53217
  - Noncarboxylic Acids
    - Phosphorus Acids: 1
      - Phosphinic Acids: 18
        (18)F-PSMA-11: 9
- Phosphorus Compounds: 84
  - Phosphorus Acids: 1
    - Phosphinic Acids: 18
      - (18)F-PSMA-11: 9

Experts

1.	De Man, Kathia: 5 articles (11/2022 - 12/2019)
2.	Kersemans, Ken: 5 articles (11/2022 - 12/2019)
3.	Piron, Sarah: 5 articles (11/2022 - 12/2019)
4.	Van Laeken, Nick: 5 articles (11/2022 - 12/2019)
5.	De Vos, Filip: 4 articles (11/2022 - 12/2019)
6.	Ost, Piet: 4 articles (11/2022 - 12/2019)
7.	Fonteyne, Valérie: 3 articles (11/2022 - 12/2019)
8.	Lumen, Nicolaas: 3 articles (11/2022 - 12/2019)
9.	Schelfhout, Vanessa: 3 articles (11/2022 - 02/2020)
10.	Decaestecker, Karel: 2 articles (11/2022 - 12/2019)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 10/01/2022 - "18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions." 10/01/2022 - "In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. " 10/01/2022 - "Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management." 12/01/2019 - "Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer." 02/24/2020 - "Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer."
2.	Neoplasms (Cancer) 12/03/2020 - "Delayed imaging with the latter may improve tumor visualization, while no additional benefits could be found for late 18F-PSMA-11 imaging. " 11/01/2016 - "The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). " 05/01/2022 - "The prostate tumor showed inhomogeneous hyperintensity on T2-weighted images due to high extracellular mucin content and inhomogeneous 18F-PSMA-11 uptake with SUVmax of 12.5. " 12/03/2020 - "Tumor uptake of 18F-PSMA-11 showed a similar trend over time as 68Ga-PSMA-11, although all uptake parameter curves of the latter were considerably lower. " 11/01/2016 - "18F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. "
3.	Body Weight (Weight, Body) 12/01/2019 - "Methods: Six patients (aged 62-68 y; mean, 66 ± 2 y) with suspected prostate cancer recurrence after previous treatment were administered 2 MBq of 18F-PSMA-11 per kilogram of body weight and then underwent low-dose PET/CT imaging at 0, 20, 50, 90, and 300 min after injection. "
4.	Adenocarcinoma 05/01/2022 - "We describe MRI and 18F-PSMA-11 PET/MRI findings in a case of prostate adenocarcinoma with mucinous features. " 05/01/2022 - "18F-PSMA-11 PET/MRI in Prostate Adenocarcinoma With Mucinous Features."

Related Drugs and Biologics

1.	gallium 68 PSMA-11
2.	Peptides (Polypeptides)
3.	Mucins
4.	aluminum fluoride

Related Therapies and Procedures

1.	PET protocol